Evidence map›Paper›PMID 40038506›Full record

ArticleScientific reports2025

Characterizing heterogeneity in Alzheimer's disease progression: a semiparametric model.

Fatih Gelir, Suneel Babu Chatla, Md Shenuarin Bhuiyan, Elizabeth A Disbrow, Steven A Conrad, John A Vanchiere, Christopher G Kevil, Emrah Gecili, Mohammad Alfrad Nobel Bhuiyan

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fatih GelirDivision of Clinical Informatics, Department of Medicine, Louisiana State University Health Sciences Center at Shreveport, PO Box 33932, Shreveport, LA, 71130-3932, USA.
Suneel Babu ChatlaDepartment of Mathematical Sciences, University of Texas at El Paso, El Paso, TX, 79968, USA.
Md Shenuarin BhuiyanDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USA.
Elizabeth A DisbrowDepartment of Pharmacology, Toxicology and Neuroscience, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USA.
Steven A ConradDivision of Clinical Informatics, Department of Medicine, Louisiana State University Health Sciences Center at Shreveport, PO Box 33932, Shreveport, LA, 71130-3932, USA.
John A VanchiereDepartment of Pediatrics, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USA.
Christopher G KevilDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USA.
Emrah GeciliDivision of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. Emrah.Gecili@cchmc.org.
Mohammad Alfrad Nobel BhuiyanDivision of Clinical Informatics, Department of Medicine, Louisiana State University Health Sciences Center at Shreveport, PO Box 33932, Shreveport, LA, 71130-3932, USA. Nobel.Bhuiyan@lsuhs.edu.

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Stress Exacerbates Myocardial Ischemic Injury by Blocking Estrogen's Antidoxidant Protection in the Female HeartP20GM121307 · NIGMS · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Vesna Tesic · 2018 to 2026
$23.6M
Sigmar1 in lipid metabolismR01HL145753 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI BHUIYAN, MD. SHENUARIN · 2019 to 2023
$2.6M
Novel mitophagy regulatory mechanism in heart failureR01HL172970 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Md. Shenuarin Bhuiyan · 2024 to 2026
$2.0M
CSE regulation of vascular remodelingR01HL149264 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI KEVIL, CHRISTOPHER G · 2020 to 2023
$1.7M
NHLBI NIH HHS R01 HL145753NHLBI NIH HHS R01 HL149264NHLBI NIH HHS R01 HL172970NIA NIH HHS U01 AG024904NIGMS NIH HHS P20 GM121307
6 · The paper itself

Abstract

The progression of Alzheimer's disease (AD), a leading cause of dementia worldwide, is known for its variability and complexity, challenging the conventional methods of monitoring and predicting disease trajectories. This study introduces a semiparametric modeling approach to analyze longitudinal cognitive and imaging data. We studied two different outcome variables from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database: the Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS13) scores and ventricular volumes [Formula: see text]. Unlike traditional linear mixed effects models, semiparametric models do not assume a linear AD progression over time. Semiparametric models offer the advantage of capturing the non-linear features of AD progression, such as cognitive decline and neurodegeneration, represented by changes in ADAS13 scores and ventricular enlargement, respectively. By integrating regression splines and mixed modeling techniques, we provide a nuanced understanding of AD progression that captures the heterogeneity of disease trajectories. Our analysis reveals variations in the timing and degree of cognitive decline and neurodegeneration among AD patients, underlining the need for personalized approaches for monitoring and managing AD. This study's findings contribute to the modeling of AD progression and offer potential implications for interventions and prognostic assessments in clinical and research settings.

Indexed as

Alzheimer DiseaseAgedAged, 80 and overCognitive DysfunctionDisease ProgressionFemaleHumansLongitudinal StudiesMagnetic Resonance ImagingMaleModels, StatisticalNeuroimagingADAS13ADNI databaseAlzheimer’s diseaseCognitive declineNeurodegenerationSemiparametric modelingSplinesVentricular volumes

Identifiers

PMID40038506
PMCPMC11880422

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.